Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Quantec Limited manages a company patent portfolio that is currently active in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action for the company. This 1 pending office action is being handled by 1 distinct examiner, which indicates a concentrated prosecution effort. Furthermore, the portfolio is situated within 1 distinct art unit, reflecting a specific technical focus for the pending matter.
REGLAS, GEORGIANA C is the busiest examiner for this portfolio. This examiner is responsible for 1 busiest examiner pending office action. Since there is only a single pending action in total, this examiner is managing the entire current workload for the company. This arrangement means that the company's interaction with the patent office is currently limited to this specific individual and the Biotechnology & Pharmaceuticals sector. Practitioners should note that the prosecution strategy is entirely dependent on the feedback from this examiner. The presence of 1 distinct art unit suggests a highly targeted approach to patenting at this stage. This streamlined structure allows for a clear focus on the requirements of the 1 distinct examiner involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGLAS, GEORGIANA C | 1 | 39.2% | +33.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838383 | COMBINATION, THERAPEUTIC USES AND PROPHYLACTIC USES | REGLAS, GEORGIANA C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838383 | COMBINATION, THERAPEUTIC USES AND PROPHYLACTIC USES | REGLAS, GEORGIANA C | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838383 | COMBINATION, THERAPEUTIC USES AND PROPHYLACTIC USES | REGLAS, GEORGIANA C | 1653 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQuantec Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Georgiana C Reglas has the most, with 1 of Quantec Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
